+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lymphatic Filariasis Drug"

Elephantiasis Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Elephantiasis Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • July 2023
  • 87 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

Lymphatic Filariasis (LF) is a neglected tropical disease caused by parasitic worms. It is spread by mosquitoes and affects millions of people in tropical and subtropical regions. Infectious Diseases Drugs are used to treat LF, including diethylcarbamazine (DEC), albendazole, ivermectin, and doxycycline. DEC is the most commonly used drug for LF, and is used in combination with albendazole and ivermectin. DEC is used to kill the adult worms, while albendazole and ivermectin are used to kill the larvae. Doxycycline is used to reduce the inflammation caused by the infection. The LF Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Merck & Co., GlaxoSmithKline, Sanofi, Pfizer, Novartis, and Bayer. These companies offer a range of products, including DEC, albendazole, ivermectin, and doxycycline. Show Less Read more